These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 31747004)

  • 21. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study.
    Sayin BY; Al Mahmeed W; Ragy HI; Elbahry A; Virdone S; Kakkar AK; Ersanlı M; Oto A
    Adv Ther; 2021 May; 38(5):2391-2405. PubMed ID: 33772428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher Risk of Ischemic Events in Secondary Prevention for Patients With Persistent Than Those With Paroxysmal Atrial Fibrillation.
    Koga M; Yoshimura S; Hasegawa Y; Shibuya S; Ito Y; Matsuoka H; Takamatsu K; Nishiyama K; Todo K; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Yagita Y; Kario K; Shiozawa M; Sato S; Yamagami H; Arihiro S; Toyoda K;
    Stroke; 2016 Oct; 47(10):2582-8. PubMed ID: 27531346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of heart rate during atrial fibrillation on clinical outcomes in elderly non-valvular atrial fibrillation patients: ANAFIE Registry sub-cohort study.
    Ikeda T; Yamashita T; Akao M; Atarashi H; Koretsune Y; Okumura K; Shimizu W; Suzuki S; Tsutsui H; Toyoda K; Hirayama A; Yasaka M; Yamaguchi T; Teramukai S; Kimura T; Morishima Y; Takita A; Inoue H
    J Cardiol; 2023 May; 81(5):441-449. PubMed ID: 36427691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry.
    Pope MK; Atar D; Svilaas A; Hole T; Nielsen JD; Hintze U; Crisby M; Raatikainen P; Airaksinen KEJ; Virdone S; Pieper K; Kayani G; Le Heuzey JY; Steffel J; Stepinska J; Bassand JP; Camm AJ;
    Ann Med; 2021 Dec; 53(1):485-494. PubMed ID: 33818226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
    Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK;
    PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.
    Bassand JP; Accetta G; Camm AJ; Cools F; Fitzmaurice DA; Fox KA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Mantovani LG; Misselwitz F; Ten Cate H; Turpie AG; Verheugt FW; Kakkar AK;
    Eur Heart J; 2016 Oct; 37(38):2882-2889. PubMed ID: 27357359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry.
    Verheugt FWA; Gao H; Al Mahmeed W; Ambrosio G; Angchaisuksiri P; Atar D; Bassand JP; Camm AJ; Cools F; Eikelboom J; Kayani G; Lim TW; Misselwitz F; Pieper KS; van Eickels M; Kakkar AK;
    Eur Heart J; 2018 Feb; 39(6):464-473. PubMed ID: 29281086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Steinberg BA; Peterson ED; Kim S; Thomas L; Gersh BJ; Fonarow GC; Kowey PR; Mahaffey KW; Sherwood MW; Chang P; Piccini JP; Ansell J;
    Circulation; 2015 Feb; 131(5):488-94. PubMed ID: 25499873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
    Steinberg BA; Kim S; Thomas L; Fonarow GC; Hylek E; Ansell J; Go AS; Chang P; Kowey P; Gersh BJ; Mahaffey KW; Singer DE; Piccini JP; Peterson ED;
    Circulation; 2014 May; 129(20):2005-12. PubMed ID: 24682387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.
    Lip GY; Rushton-Smith SK; Goldhaber SZ; Fitzmaurice DA; Mantovani LG; Goto S; Haas S; Bassand JP; Camm AJ; Ambrosio G; Janský P; Al Mahmeed W; Oh S; van Eickels M; Raatikainen P; Steffel J; Oto A; Kayani G; Accetta G; Kakkar AK;
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2 Suppl 1):S12-20. PubMed ID: 25714828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry.
    Yamashita Y; Takagi D; Hamatani Y; Iguchi M; Masunaga N; Esato M; Chun YH; Itoh H; Nishimura M; Wada H; Hasegawa K; Ogawa H; Abe M; Akao M
    Heart Vessels; 2016 Dec; 31(12):2025-2034. PubMed ID: 26973346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.
    Goto S; Angchaisuksiri P; Bassand JP; Camm AJ; Dominguez H; Illingworth L; Gibbs H; Goldhaber SZ; Goto S; Jing ZC; Haas S; Kayani G; Koretsune Y; Lim TW; Oh S; Sawhney JPS; Turpie AGG; van Eickels M; Verheugt FWA; Kakkar AK;
    J Am Heart Assoc; 2019 Feb; 8(3):e010510. PubMed ID: 30717616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan　- Insight From the ANAFIE (All Nippon AF In Elderly) Registry.
    Hiasa KI; Kaku H; Inoue H; Yamashita T; Akao M; Atarashi H; Koretsune Y; Okumura K; Shimizu W; Ikeda T; Toyoda K; Hirayama A; Yasaka M; Yamaguchi T; Teramukai S; Kimura T; Kaburagi J; Takita A; Tsutsui H
    Circ J; 2020 Feb; 84(3):388-396. PubMed ID: 31969518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
    BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: A systematic review and meta-analysis.
    Lilli A; Di Cori A; Zacà V
    Clin Cardiol; 2017 Sep; 40(9):641-647. PubMed ID: 28471498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
    Steinberg BA; Gao H; Shrader P; Pieper K; Thomas L; Camm AJ; Ezekowitz MD; Fonarow GC; Gersh BJ; Goldhaber S; Haas S; Hacke W; Kowey PR; Ansell J; Mahaffey KW; Naccarelli G; Reiffel JA; Turpie A; Verheugt F; Piccini JP; Kakkar A; Peterson ED; Fox KAA; ;
    Am Heart J; 2017 Dec; 194():132-140. PubMed ID: 29223431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry.
    Camm AJ; Accetta G; Al Mahmeed W; Ambrosio G; Goldhaber SZ; Haas S; Jansky P; Kayani G; Misselwitz F; Oh S; Oto A; Raatikainen P; Steffel J; van Eickels M; Kakkar AK;
    BMJ Open; 2017 Mar; 7(3):e014579. PubMed ID: 28264833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.